• 1
    de Carvalho E, Ivantes CA, Bezerra JA. Extrahepatic biliary atresia: current concepts and future directions. J Pediatr (Rio J) 2007; 83: 105-120.
  • 2
    Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.
  • 3
    Chen L, Goryachev A, Sun J, Kim P, Zhang H, Phillips MJ, et al. Altered expression of genes involved in hepatic morphogenesis and fibrogenesis are identified by cDNA microarray analysis in biliary atresia. HEPATOLOGY 2003; 38: 567-576.
  • 4
    Eddy AA. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost 2009; 101: 656-664.
  • 5
    Marchand-Adam S, Fabre A, Mailleux AA, Marchal J, Quesnel C, Kataoka H, et al. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 58-66.
  • 6
    Uchida K, Inoue M, Otake K, Yoshiyama S, Toiyama Y, Hiro J, et al. The significance of serum hepatocyte growth factor levels in planning follow-up of postoperative jaundice-free patients with biliary atresia. J Pediatr Surg 2006; 41: 1657-1662.
  • 7
    Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 2005; 579: 1945-1950.
  • 8
    Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-36725.
  • 9
    Szabo R, Hobson JP, List K, Molinolo A, Lin CY, Bugge TH. Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J Biol Chem 2008; 283: 29495-29504.
  • 10
    Lee MS, Kiyomiya K, Benaud C, Dickson RB, Lin CY. Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells. Am J Physiol Cell Physiol 2005; 288: C932-941.
  • 11
    Kataoka H, Suganuma T, Shimomura T, Itoh H, Kitamura N, Nabeshima K, et al. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem 1999; 47: 673-682.
  • 12
    Tanaka H, Nagaike K, Takeda N, Itoh H, Kohama K, Fukushima T, et al. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for branching morphogenesis in the chorioallantoic placenta. Mol Cell Biol 2005; 25: 5687-5698.
  • 13
    Szabo R, Hobson JP, Christoph K, Kosa P, List K, Bugge TH. Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice. Development 2009; 136: 2653-2663.
  • 14
    Sasaki M, Ikeda H, Kataoka H, Nakanuma Y. Augmented expression of hepatocytes growth factor activator inhibitor type 1 (HAI-1) in intrahepatic small bile ducts in primary biliary cirrhosis. Virchows Arch 2006; 449: 462-471.
  • 15
    Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. HEPATOLOGY 2004; 39: 1739-1745.
  • 16
    Tan CE, Driver M, Howard ER, Moscoso GJ. Extrahepatic biliary atresia: a first-trimester event? Clues from light microscopy and immunohistochemistry. J Pediatr Surg 1994; 29: 808-814.
  • 17
    Crosby HA, Hubscher SG, Joplin RE, Kelly DA, Strain AJ. Immunolocalization of OV-6, a putative progenitor cell marker in human fetal and diseased pediatric liver. HEPATOLOGY 1998; 28: 980-985.
  • 18
    Beierle EA, Vauthey JN, Moldawer LL, Copeland EM 3rd. Hepatic tumor necrosis factor-alpha production and distant organ dysfunction in a murine model of obstructive jaundice. Am J Surg 1996; 171: 202-206.
  • 19
    Tanimizu N, Saito H, Mostov K, Miyajima A. Long-term culture of hepatic progenitors derived from mouse Dlk+ hepatoblasts. J Cell Sci 2004; 117: 6425-6434.
  • 20
    Lee HS, Miau LH, Chen CH, Chiou LL, Huang GT, Yang PM, et al. Differential role of p38 in IL-1alpha induction of MMP-9 and MMP-13 in an established liver myofibroblast cell line. J Biomed Sci 2003; 10: 757-765.
  • 21
    Kruglov EA, Jain D, Dranoff JA. Isolation of primary rat liver fibroblasts. J Investig Med 2002; 50: 179-184.
  • 22
    Hoshino Y, Wyatt RG, Flores J, Midthun K, Kapikian AZ. Serotypic characterization of rotaviruses derived from asymptomatic human neonatal infections. J Clin Microbiol 1985; 21: 425-430.
  • 23
    Wu SJ, Yang YH, Tsuneyama K, Leung PS, Illarionov P, Gershwin ME, et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. HEPATOLOGY 2011; 53: 915-925.
  • 24
    Turner R, Lozoya O, Wang Y, Cardinale V, Gaudio E, Alpini G, et al. Human hepatic stem cell and maturational liver lineage biology. HEPATOLOGY 2011; 53: 1035-1045.
  • 25
    Kobayashi H, Yamataka A, Lane GJ, Miyano T. Levels of circulating antiinflammatory cytokine interleukin-1 receptor antagonist and proinflammatory cytokines at different stages of biliary atresia. J Pediatr Surg 2002; 37: 1038-1041.
  • 26
    Tan CE, Chan VS, Yong RY, Vijayan V, Tan WL, Fook Chong SM, et al. Distortion in TGF beta 1 peptide immunolocalization in biliary atresia: comparison with the normal pattern in the developing human intrahepatic bile duct system. Pathol Int 1995; 45: 815-824.
  • 27
    Abukawa D, Nakagawa M, Iinuma K, Nio M, Ohi R, Goto J. Hepatic and serum bile acid compositions in patients with biliary atresia: a microanalysis using gas chromatography-mass spectrometry with negative ion chemical ionization detection. Tohoku J Exp Med 1998; 185: 227-237.
  • 28
    Honsawek S, Klaikeaw N, Vejchapipat P, Chongsrisawat V, Ruangvejvorachai P, Poovorawan Y. Cyclooxygenase-2 overexpression is associated with clinical outcome in biliary atresia. Eur J Pediatr Surg 2010; 20: 164-168.
  • 29
    Tuchweber B, Desmouliere A, Bochaton-Piallat ML, Rubbia-Brandt L, Gabbiani G. Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. Lab Invest 1996; 74: 265-278.
  • 30
    Ramm GA, Nair VG, Bridle KR, Shepherd RW, Crawford DH. Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fibrogenesis in biliary atresia. Am J Pathol 1998; 153: 527-535.
  • 31
    Lamireau T, Le Bail B, Boussarie L, Fabre M, Vergnes P, Bernard O, et al. Expression of collagens type I and IV, osteonectin and transforming growth factor beta-1 (TGFbeta1) in biliary atresia and paucity of intrahepatic bile ducts during infancy. J Hepatol 1999; 31: 248-255.
  • 32
    Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, Jacquemin P, et al. The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development 2002; 129: 1819-1828.
  • 33
    Glaser SS, Gaudio E, Miller T, Alvaro D, Alpini G. Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med 2009; 11: e7.
  • 34
    Diaz R, Kim JW, Hui JJ, Li Z, Swain GP, Fong KS, et al. Evidence for the epithelial to mesenchymal transition in biliary atresia fibrosis. Hum Pathol 2008; 39: 102-115.